There's A Lot To Like About Shenzhen New Industries Biomedical Engineering's (SZSE:300832) Upcoming CN¥1.00 Dividend
There's A Lot To Like About Shenzhen New Industries Biomedical Engineering's (SZSE:300832) Upcoming CN¥1.00 Dividend
Shenzhen New Industries Biomedical Engineering Co., Ltd. (SZSE:300832) is about to trade ex-dividend in the next 4 days. The ex-dividend date is usually set to be one business day before the record date which is the cut-off date on which you must be present on the company's books as a shareholder in order to receive the dividend. The ex-dividend date is of consequence because whenever a stock is bought or sold, the trade takes at least two business day to settle. Therefore, if you purchase Shenzhen New Industries Biomedical Engineering's shares on or after the 15th of May, you won't be eligible to receive the dividend, when it is paid on the 15th of May.
深圳新产业生物医学工程有限公司(SZSE: 300832)即将在未来4天内进行除息交易。除息日通常设置为记录日期前一个工作日,即您必须作为股东出现在公司账簿上才能获得股息的截止日期。除息日之所以如此,是因为无论何时买入或卖出股票,交易都需要至少两个工作日才能结算。因此,如果您在5月15日当天或之后购买深圳新产业生物医学工程的股票,则没有资格获得5月15日支付的股息。
The company's next dividend payment will be CN¥1.00 per share. Last year, in total, the company distributed CN¥1.00 to shareholders. Calculating the last year's worth of payments shows that Shenzhen New Industries Biomedical Engineering has a trailing yield of 1.3% on the current share price of CN¥77.83. Dividends are an important source of income to many shareholders, but the health of the business is crucial to maintaining those dividends. We need to see whether the dividend is covered by earnings and if it's growing.
该公司的下一次股息将为每股1.00元人民币。去年,该公司总共向股东分发了1.00元人民币。计算去年的付款额显示,深圳新产业生物医学工程的追踪收益率为1.3%,而目前的股价为77.83元人民币。股息是许多股东的重要收入来源,但业务的健康状况对于维持这些股息至关重要。我们需要看看股息是否由收益支付,以及股息是否在增长。
Dividends are usually paid out of company profits, so if a company pays out more than it earned then its dividend is usually at greater risk of being cut. Fortunately Shenzhen New Industries Biomedical Engineering's payout ratio is modest, at just 46% of profit. A useful secondary check can be to evaluate whether Shenzhen New Industries Biomedical Engineering generated enough free cash flow to afford its dividend. Fortunately, it paid out only 48% of its free cash flow in the past year.
股息通常从公司利润中支付,因此,如果公司支付的股息超过其收入,则其股息被削减的风险通常更大。幸运的是,深圳新产业生物医学工程的派息率不高,仅占利润的46%。一项有用的辅助检查可以用来评估深圳新产业生物医学工程是否产生了足够的自由现金流来支付其股息。幸运的是,在过去的一年中,它仅支付了自由现金流的48%。
It's encouraging to see that the dividend is covered by both profit and cash flow. This generally suggests the dividend is sustainable, as long as earnings don't drop precipitously.
令人鼓舞的是,股息由利润和现金流共同支付。这通常表明,只要收益不急剧下降,股息是可持续的。
Click here to see the company's payout ratio, plus analyst estimates of its future dividends.
点击此处查看该公司的派息率,以及分析师对其未来股息的估计。
![historic-dividend](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240511/0-8e5c6e40bdb4eadbd01acb867a1139fa-0-e070444861b42a1bf2e3c6e56d47294a.png/big)
Have Earnings And Dividends Been Growing?
收益和股息一直在增长吗?
Stocks in companies that generate sustainable earnings growth often make the best dividend prospects, as it is easier to lift the dividend when earnings are rising. Investors love dividends, so if earnings fall and the dividend is reduced, expect a stock to be sold off heavily at the same time. For this reason, we're glad to see Shenzhen New Industries Biomedical Engineering's earnings per share have risen 17% per annum over the last five years. Earnings per share are growing rapidly and the company is keeping more than half of its earnings within the business; an attractive combination which could suggest the company is focused on reinvesting to grow earnings further. Fast-growing businesses that are reinvesting heavily are enticing from a dividend perspective, especially since they can often increase the payout ratio later.
实现可持续收益增长的公司的股票通常具有最佳的股息前景,因为收益上升时更容易提高股息。投资者喜欢分红,因此,如果收益下降而股息减少,预计股票将同时被大量抛售。出于这个原因,我们很高兴看到深圳新产业生物医学工程的每股收益在过去五年中每年增长17%。每股收益快速增长,该公司将一半以上的收益保留在业务中;这种有吸引力的组合可能表明该公司专注于再投资以进一步增加收益。从股息的角度来看,进行大量再投资的快速增长的企业具有吸引力,尤其是因为它们通常可以在以后提高派息率。
Many investors will assess a company's dividend performance by evaluating how much the dividend payments have changed over time. Shenzhen New Industries Biomedical Engineering's dividend payments per share have declined at 11% per year on average over the past four years, which is uninspiring. It's unusual to see earnings per share increasing at the same time as dividends per share have been in decline. We'd hope it's because the company is reinvesting heavily in its business, but it could also suggest business is lumpy.
许多投资者将通过评估股息支付在一段时间内发生了多大变化来评估公司的股息表现。在过去四年中,深圳新产业生物医学工程的每股股息平均每年下降11%,这并不令人鼓舞。每股收益在每股股息下降的同时增加是不寻常的。我们希望这是因为该公司正在对其业务进行大量再投资,但这也可能表明业务不景气。
Final Takeaway
最后的外卖
Is Shenzhen New Industries Biomedical Engineering worth buying for its dividend? Shenzhen New Industries Biomedical Engineering has grown its earnings per share while simultaneously reinvesting in the business. Unfortunately it's cut the dividend at least once in the past four years, but the conservative payout ratio makes the current dividend look sustainable. Shenzhen New Industries Biomedical Engineering looks solid on this analysis overall, and we'd definitely consider investigating it more closely.
深圳新产业生物医学工程的分红值得买吗?深圳新产业生物医学工程增加了每股收益,同时对该业务进行了再投资。不幸的是,它在过去四年中至少削减过一次股息,但是保守的派息率使当前的股息看起来是可持续的。总体而言,深圳新产业生物医学工程的分析看起来很扎实,我们一定会考虑对其进行更仔细的研究。
On that note, you'll want to research what risks Shenzhen New Industries Biomedical Engineering is facing. Our analysis shows 1 warning sign for Shenzhen New Industries Biomedical Engineering and you should be aware of this before buying any shares.
关于这一点,你需要研究深圳新产业生物医学工程面临的风险。我们的分析显示,深圳新产业生物医学工程有1个警告信号,在购买任何股票之前,您应该注意这一点。
Generally, we wouldn't recommend just buying the first dividend stock you see. Here's a curated list of interesting stocks that are strong dividend payers.
通常,我们不建议只购买你看到的第一只股息股票。以下是精选的具有强大股息支付能力的有趣股票清单。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。